• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

9.045 +0.315 (+3.61%)
Delayed Quote Updated: 3:06 PM EST, Nov 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,634,304
Open 8.800
Bid (Size) 9.040 (100)
Ask (Size) 9.050 (500)
Prev. Close 8.730
Today's Range 8.670 - 9.130
52wk Range 3.430 - 10.82
Shares Outstanding 77,740,000
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Verastem Bets on Higher Cancer Drug Dose as It Maps Potential Approval Path ↗
Today 9:13 EST
Verastem (NASDAQ:VSTM) plans to advance a 900-milligram dose of its experimental KRAS G12D inhibitor VS-7375 across cancer indications, citing evidence of a dose response and a tolerability profile... 
Via MarketBeat
Verastem (NASDAQ:VSTM) Passes Minervini Trend Template but Setup Rating Signals Patience ↗
November 10, 2026
Via Chartmill

Performance

52-Week Range 16.4% below 52-week high
9.045
3.4352W Low 10.8252W High
1 Week 10.4% below 1-week high
7.721W Low 10.101W High

Verastem, Inc. - Common Stock (VSTM) traded between $3.43 and $10.82 over the past 52 weeks and last traded at $9.04, 16.4% below its 52-week high. Over the past week it ranged between $7.72 and $10.10.

Past 12 Months
-8.2%
+9.6%
+28.3%
+95.4%
+25.1%
+9.6%
1W -$0.80
1M +$0.79
3M +$2.00
6M +$4.42
YTD +$1.81
1Y +$0.79

VSTM was +9.6% over the past year, +95.4% over six months, +25.1% year to date, -8.2% in the last week.

12 Months vs Market
VSTM
+9.6%
DIA
+10.7%
SPY
+11.6%
QQQ
+11.0%
IWM
+16.0%

Over the past 12 months VSTM returned +9.6% versus DIA (Dow) +10.7%, SPY (S&P 500) +11.6%, QQQ (Nasdaq 100) +11.0% and IWM (Russell 2000) +16.0%.

Volume & Liquidity 0.48× 3-mo avg
Today 1,634,304 3-mo avg 3.4M
1W
3.7M
1M
5.6M
3M
3.4M
6M
3.0M
YTD
2.6M
1Y
2.5M

VSTM most recently traded 1,634,304 shares against a 3-month average daily volume of 3.4M.

More News

Read More
News headline image
Verastem Targets Accelerated Approval for Pancreatic Cancer Drug, Expands Trial Plans ↗
November 10, 2026
Via MarketBeat
News headline image
What Verastem (VSTM) Said on Its Q3 Earnings Call ↗
November 06, 2026
Via MarketBeat
Topics Earnings
News headline image
Verastem (VSTM) Q3 2026 Earnings Call Transcript ↗
November 06, 2026
Via The Motley Fool
Topics Earnings
News headline image
Verastem Oncology Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
November 05, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Participate in Upcoming November Investor Conferences
November 02, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026
October 22, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase III ↗
October 14, 2026
Via MarketBeat
News headline image
Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
October 14, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan
October 14, 2026
From Verastem Oncology
Via Business Wire
News headline image
VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)
October 14, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 05, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026
October 02, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer
September 28, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
September 24, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright ↗
September 21, 2026
Via MarketBeat
News headline image
Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers
September 08, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Participate in Upcoming September Investor Conferences
September 02, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem (VSTM) Q2 2026 Earnings Call Transcript ↗
August 13, 2026
Via The Motley Fool
Topics Earnings
News headline image
Verastem Q2 Earnings Call Highlights ↗
August 07, 2026
Via MarketBeat
Topics Earnings
News headline image
Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
August 06, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
July 28, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
July 23, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
July 22, 2026
From Verastem Oncology
Via Business Wire

Frequently Asked Questions

Is Verastem, Inc. - Common Stock publicly traded?
Yes, Verastem, Inc. - Common Stock is publicly traded.
What exchange does Verastem, Inc. - Common Stock trade on?
Verastem, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Verastem, Inc. - Common Stock?
The ticker symbol for Verastem, Inc. - Common Stock is VSTM on the Nasdaq Stock Market
What is the current price of Verastem, Inc. - Common Stock?
The current price of Verastem, Inc. - Common Stock is 9.045
When was Verastem, Inc. - Common Stock last traded?
The last trade of Verastem, Inc. - Common Stock was at 11/11/26 03:06 PM ET
What is the market capitalization of Verastem, Inc. - Common Stock?
The market capitalization of Verastem, Inc. - Common Stock is 703.16M
How many shares of Verastem, Inc. - Common Stock are outstanding?
Verastem, Inc. - Common Stock has 703M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap